Eric Baudin

Eric Baudin

Auto-generated profile, based on publicly available information

Eric Baudin

Institut Gustave-Roussy, Villejuif, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GAGuillaume Assié
Guillaume Assié
GAGuillemette Antoni
Guillemette Antoni
FTFrédérique Tissier
Frédérique Tissier
BCBernard Caillou
Bernard Caillou
GAGwenaelle Abiven
Gwenaelle Abiven
EBEric Baudin
Eric Baudin
Context: Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized. Objective: The objective of the study was to describe the clinical presentation of metastatic ACC and determine prognostic factors for survival. Design: This was a retrospective cohort study (1988–2004). Setting: The study was conducted in an institutional practice. Patients: Participants included 124 consecutive patients with metastatic ACC, 70 from Gustave-Roussy Institute (main cohort) and 54 patients from the Cochin Hospital (validation cohort). Clinical data concerning all patients, histopathologic slides of primary tumors (44 in the main cohort and 40 in the validation cohort), and molecular biology data on 15 primary tumors (main cohort) were analyzed. Intervention: There was no intervention. Main Outcome: The main outcome was the specific survival after discovery of the first metastasis (Kaplan-Meier method). This included univariate analysis on the main cohort, confirmed on the validation cohort and then analyzed in a multivariate analysis. Results: In the main cohort, overall median survival was 20 months. In univariate analysis, the presence of hepatic and bone metastases, the number of metastatic lesions and the number of tumoral organs at the time of the first metastasis, a high mitotic rate (>20 per 50 high-power field), and atypical mitoses in the primary tumor predicted survival (P = 0.05, 0.003, 0.046, 0.001, 0.01, and < 0.001, respectively). The number of tumoral organs and a high mitotic rate were confirmed on the validation cohort (P = 0.009 and 0.03, respectively). These two parameters were confirmed in multivariate analysis (P = 0.0058 and 0.049). Conclusion: Metastatic ACC is a heterogeneous disease with poor outcome. The combination of the number of tumoral organs at the time of the first metastasis and the mitotic rate can predict different outcomes.

15 September 2001 in Cancer
Verified
Journal Article
Open access
PDF file
EBE. Baudin
E. Baudin
GPGabriella Pellegriti
Gabriella Pellegriti
MBM. Bonnay
M. Bonnay
APA. Penfornis
A. Penfornis
ALA. Laplanche
A. Laplanche
MSM. Schlumberger
M. Schlumberger
BACKGROUND It has been suggested recently that 1,1‐dichlorodiphenildichloroethane (o,p′DDD) elicits a dose effect relation in the treatment of patients with adrenocortical carcinoma (ACC). The authors performed a single‐center, prospective study with two major objectives: 1) to confirm the interest of plasma o,p′DDD level measurement as a prognostic factor of response to o,p′DDD therapy; and 2) to look for parameters associated with a therapeutic plasma o,p′DDD level, especially the daily o,p′DDD dose. METHODS Since 1995, patients with ACC who were referred to the Gustave‐Roussy Institute have been enrolled prospectively in the study. Therapy with o,p′DDD was given as first‐line therapy in 13 patients with metastatic disease or as adjuvant therapy in 11 patients. Oral o,p′DDD was given in three separate doses up to at least 6–12 g per day together with substitutive adrenal therapy. Plasma o,p′DDD levels were measured using high‐performance liquid chromatography every 2 months. The o,p′DDD therapy was monitored to achieve plasma o,p′DDD levels within 14–20 mg/L. World Health Organization criteria were used to evaluate tumor response and toxicity. RESULTS Twenty‐four patients with ACC were studied, and a plasma o,p′DDD level > 14 mg/L was achieved in 14 patients (58%). An objective tumor response was observed in four patients with metastatic lesions (31%): One was response was complete, and three were objective hormonal responses. These tumor responses were observed among the six patients who achieved therapeutic plasma o,p′DDD levels. In contrast, no response was observed among the seven patients with plasma o,p′DDD levels that remained consistently low. Eight of 11 patients who received o,p′DDD as adjuvant therapy had disease recurrence, although the plasma o,p′DDD level was > 14 mg/L in 6 patients. Grade 3 or 4 neurologic toxicity was observed in three patients (12%), all with an o,p′DDD level > 20 mg/L. The daily o,p′DDD dose was the only parameter associated with the highest plasma o,p′DDD trough levels: It explained 35% of the variability in the plasma o,p′DDD level. A median interval of 3.7 months was found necessary to achieve the highest o,p′DDD trough levels. CONCLUSIONS The results confirm the prognostic impact of the plasma o,p′DDD level in patients with metastatic ACC and its interest in avoiding toxicity. Cancer 2001;92:1385–92. © 2001 American Cancer Society.

1 October 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SHSégolène Hescot
Ségolène Hescot
SLSophie Leboulleux
Sophie Leboulleux
LALaurence Amar
Laurence Amar
DVDelphine Vezzosi
Delphine Vezzosi
IBIsabelle Borget
Isabelle Borget
FNfor the French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks)
for the French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks)
Context: The natural history of malignant pheochromocytoma or paragangliomas (MPP) remain unknown. Objective: The primary aim of this study was to define progression-free survival at 1 year in therapy-naive patients with MPP. Secondary objectives were to characterize MPP and to look for prognostic parameters for progression at 1 year. Design and Setting: The files of MPP followed up between January 2001 and January 2011 in two French Endocrine Networks were retrospectively reviewed. Therapy-naive patients were enrolled. Main Outcome Measures: The main outcome was progression-free survival at 1 year in therapy-naive MPP patients according to Response Evaluation Criteria In Solid Tumors 1.1 criteria. Results: Ninety files (46 men, 44 women, mean age of 47.5 ± 15 years) were reviewed on site by one investigator. MPP characteristics were as follows: presence of an adrenal primary, a mitotic count exceeding 5 per high power field, hypertension, inherited disease, and presence of bone metastases in 50%, 22%, 60%, 49%, and 56% patients, respectively. Fifty-seven of the 90 patients with MPP (63%) were classified as therapy-naive. The median follow-up of these 57 patients was 2.4 years (range, 0.4–5.7). At 1 year, progression-free survival was 46% (CI 95: 33–59). Twenty-six of 30 (87%) patients with progression at 1 year had exhibited progressive disease at the first imaging workup performed after a median of 5.7 months. No prognostic parameter was identified. Conclusions: Half of the therapy-naive patients with MPP achieved stable disease at 1 year. In symptom-free patients with MPP, a wait-and-see antitumor policy seems appropriate as first line. Modality for a prospective follow-up is proposed.

1 September 2014 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
EBEric Baudin
Eric Baudin
MHMouhammed Amir Habra
Mouhammed Amir Habra
FDFrederic Deschamps
Frederic Deschamps
GCGilbert Cote
Gilbert Cote
FDFrédéric Dumont
Frédéric Dumont
Camilo JimenezCamilo Jimenez
Camilo Jimenez
Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicians with three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centers with multidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.

28 December 2001 in Cancer
Verified
Journal Article
Open access
PDF file
SLS. Leboulleux
S. Leboulleux
JTJ. P. Travagli
J. P. Travagli
BCB. Caillou
B. Caillou
ALA. Laplanche
A. Laplanche
JBJ. M. Bidart
J. M. Bidart
EBE. Baudin
E. Baudin
BACKGROUND: Multiple endocrine neoplasia type 2B (MEN 2B) is an exceptional syndrome, for which the optimal age of thyroidectomy is poorly established and the course of medullary thyroid carcinoma (MTC) is ill‐defined.PATIENTS: All the 18 patients with a MEN 2B syndrome examined at the Institut Gustave Roussy were included in a single‐center retrospective study.RESULTS: There were 9 men and 9 women with a mean age of 13 years (range, 2–27 years) at diagnosis. The diagnosis of MTC was based on the presence of a thyroid nodule or involved neck lymph nodes and on dysmorphic features of MEN 2B in 60% and 40% of the cases, respectively. The classic M918T mutation in exon 16 was found in the 16 patients in whom it was investigated. At diagnosis, 2 patients had Stage I MTC, 15 patients had Stage III, and 1 patient had Stage IV disease. T1 MTC was found in 4 patients aged 2.1–3.7 years. However, two of these patients already had N1 disease. One patient with Stage I MTC, aged 3.4 years and 2 patients with Stage III disease, aged 14 and 25 years, had undetectable basal calcitonin (CT) after initial surgery. During follow‐up, basal CT became detectable in one of three patients. Among the 15 other patients with an elevated postoperative CT level, metastases were demonstrated in 5 patients after a mean follow‐up of 2 years. Five patients died, three of MTC, one of the MEN 2B syndrome, and one of intercurrent disease. Five‐ and 10‐year overall survival rates were 85% and 75%, respectively.CONCLUSIONS: This study confirms the need for early treatment of MTC in patients with the MEN 2B syndrome, preferably within the first 6 months of life. The phenotype of MTC occurring in the MEN 2B syndrome was not more aggressive than sporadic MTC or MTC occurring in other familial syndromes. Cancer 2002;94:44–50. © 2002 American Cancer Society.

1 December 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
TKT. M. Kerkhofs
T. M. Kerkhofs
EBE. Baudin
E. Baudin
Massimo TerzoloMassimo Terzolo
Massimo Terzolo
BAB. Allolio
B. Allolio
RCR. Chadarevian
R. Chadarevian
MFM. Fassnacht
M. Fassnacht
Context: Mitotane is the only approved drug for treatment of adrenocortical carcinoma. Its pharmacokinetic properties are not fully elucidated and different dosing regimens have never been compared head to head. Objective: The objective of the study was to investigate the relationship between mitotane dose and plasma concentration comparing two dosing regimens. Design/Setting: This was a prospective, open-label, multicenter trial of a predefined duration of 12 weeks. Patients/Interventions: Forty mitotane-naïve patients with metastatic adrenocortical carcinoma were assigned to a predefined low- or high-dose regimen by the local investigator. Thirty-two patients could be evaluated in detail. Main Outcome Measure: The difference in median mitotane plasma levels between both treatment groups was measured. Results: Despite a difference in mean cumulative dose (440 ± 142 g vs 272 ± 121 g), median maximum plasma levels were not significantly different between the two groups [high dose 14.3 mg/L (range 6.3–29.7, n = 20) vs 11.3 mg/L (range 5.5–20.0, n = 12), P = .235]. Ten of 20 patients on the high-dose regimen reached plasma concentrations of 14 mg/L or greater after 46 days (range 18–81 d) compared with 4 of 12 patients on the low-dose regimen after 55 days (range 46–74 d, P = .286). All patients who reached 14 mg/L at 12 weeks displayed a level of 4.1 mg/L or greater on day 33 (100% sensitivity). There were no significant differences in frequency and severity of adverse events. Among patients not receiving concomitant chemotherapy mitotane exposure was higher in the high-dose group: 1013 ± 494 mg/L · d vs 555 ± 168 mg/L · d (P = .080). Conclusions: The high-dose starting regimen resulted in neither significantly different mitotane levels nor a different rate of adverse events, but concomitant chemotherapy influenced these results. Thus, for mitotane monotherapy the high-dose approach is favorable, whereas for combination therapy a lower dose seems reasonable.